CytoSorbents (CTSO)

Executive Summary

CytoSorbents Corporation (NASDAQ: CTSO) is a critical care company focused on blood purification therapies for life-threatening conditions in the ICU and cardiac surgery. Its flagship product, CytoSorb, is a hemoadsorption device approved in the EU and other regions for removing inflammatory cytokines, bilirubin, and myoglobin. The company also markets a portfolio of other blood purification products. Despite having a commercial product, CytoSorbents faces intense competition from other hemoperfusion devices and has struggled to achieve profitability. Recurring revenue from consumable cartridges provides a base, but expansion in the US market is pivotal. The company is pursuing FDA approval for CytoSorb in cardiac surgery, with a pivotal trial (STAR-T) ongoing. Additionally, a sepsis trial (CMS) aims to expand indications. While the technology has strong clinical rationale, adoption has been slow. Financial runway and dilution risk remain concerns. The stock trades at a low valuation reflecting these challenges, but a successful FDA approval could unlock significant upside. Near-term catalysts include data readouts and regulatory decisions.

Upcoming Catalysts (preview)

• Q4 2026FDA approval for CytoSorb in cardiac surgery (STAR-T trial)50% success
• Q3 2026Topline results from CytoSorb sepsis trial (CMS study)35% success
• Q2 2026Potential partnership or licensing deal for US commercialization40% success